TCGA-F7-8489-01A-31R-2403-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.570
- TGF_BETA_SIGNALING+0.530
- TNFA_SIGNALING_VIA_NFKB+0.530
- IL6_JAK_STAT3_SIGNALING+0.450
- ALLOGRAFT_REJECTION+0.420
- INFLAMMATORY_RESPONSE+0.410
- P53_PATHWAY+0.400
- APOPTOSIS+0.360
- IL2_STAT5_SIGNALING+0.350
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- MYC_TARGETS_V1-0.520
- E2F_TARGETS-0.370
- OXIDATIVE_PHOSPHORYLATION-0.340
- G2M_CHECKPOINT-0.310
- SPERMATOGENESIS-0.290
- DNA_REPAIR-0.190
- MYOGENESIS-0.110
- FATTY_ACID_METABOLISM-0.100
- CHOLESTEROL_HOMEOSTASIS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JWSR581E | low-grade glioma | — | 0.909 |
| 2 | TCGA-EW-A1PE-01A-11R-A144-07 | — | B | 0.908 |
| 3 | BS_S4V9E1XJ | pilocytic astrocytoma | — | 0.907 |
| 4 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.902 |
| 5 | BS_9DFBHHB5 | low-grade glioma | — | 0.899 |
| 6 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.897 |
| 7 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.892 |
| 8 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.891 |
| 9 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.890 |
| 10 | SAMN03290930 | — | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.570 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.530 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.400 | Idelalisib | — uncovered |
| APOPTOSIS | 0.360 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |